RedHill Biopharma Ltd.

6.59
0.20 (3.13%)
At close: Jan 22, 2025, 3:33 PM
6.70
1.67%
After-hours Jan 22, 2025, 06:07 PM EST

Company Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.

The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.

RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd.
RedHill Biopharma Ltd. logo
Country IL
IPO Date Jan 7, 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 53
CEO Dror Ben-Asher

Contact Details

Address:
21 Ha’arba’a Street
Tel Aviv,
IL
Website https://www.redhillbio.com

Stock Details

Ticker Symbol RDHL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001553846
CUSIP Number 757468103
ISIN Number US7574682024
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dror Ben-Asher Co-Founder, Chairman & Chief Executive Officer
Gilead Raday MPhil, MSc Chief Operating Officer
Razi Ingber Chief Financial Officer
Adi Frish Chief Corporate & Business Development Officer
Alexandra Okmian Senior Business Development & Investor Relations Manager
Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development
Guy Goldberg J.D. Chief Business Officer
Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs
Rick D. Scruggs Chief Commercial Officer, President of RedHill Biopharma Inc. & Director

Latest SEC Filings

Date Type Title
Jan 21, 2025 6-K Filing
Dec 10, 2024 6-K Filing
Dec 02, 2024 6-K Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 28, 2024 6-K Filing
Oct 22, 2024 6-K Filing
Oct 15, 2024 6-K Filing
Oct 01, 2024 6-K Filing
Sep 30, 2024 6-K Filing
Sep 18, 2024 6-K Filing